Bio-Techne Corporation · TECH · Next earnings

Bio-Techne Corporation reports Wednesday, Nov 4, 2026

TECH reports before market open with consensus EPS at $0.46 and revenue at $292.4M. Last quarter: Bio-Techne Q3: Organic Revenue Dips 2% as Spatial Biology and Cell Therapy Offset Timing Headwinds

Reports Before market open45 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.46 Calendar consensus
Consensus revenue $292.4M Calendar consensus
Report date Nov 4, 2026 Wednesday, date estimated
Session Before market open 45 days away

Where TECH left off: FY2026 Q3

Full report

Bio-Techne Q3: Organic Revenue Dips 2% as Spatial Biology and Cell Therapy Offset Timing Headwinds

EPS surprise -3.6% Reported $0.53 vs $0.55
Revenue surprise -1.5% Reported $311.4M vs $316.1M
Stock move -16.4% Event window
Subsequent drift +12.2% Up to 20 sessions

Guidance sentiment was maintained in both Q2 and Q3. However, the near-term outlook softened: management now expects flat organic growth in Q4 FY2026, with the mid-single-digit growth expectation pushed to FY2027 as biotech funding translates to spending and cell-therapy timing headwinds dissipate. In Q2, management had guided to mid-single-digit organic growth for the remainder of FY26.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Continued softness in emerging biotech spending could delay the expected FY2027 recovery.
  • Timing headwinds from large cell-therapy customers and OEM supply orders may persist.
  • Revenue concentration in a few large diagnostic customers makes the segment lumpy.
  • Academic grant funding variability and macroeconomic interest-rate environment may pressure demand.
  • Potential delays in completing the Wilson Wolf acquisition by end of 2027.

Questions analysts left open

  • Depth and timing of the emerging biotech recovery.
  • Whether FY2027 guidance will be met given the current flat Q4 outlook.
  • Competitive positioning in the RUO reagent space versus rivals.
  • Sustainability of high growth rates in COMET and Ella platforms.
  • Impact of remaining timing headwinds and OEM order timing on short-term revenue.

Ask FN2 about TECH next report

Transcript, numbers and history already loaded
What should I watch for in TECH's next earnings report?How did TECH guide last quarter, and is consensus above or below that?Give me the bull and bear case going into TECH earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the TECH recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent TECH quarters

All TECH earnings
-16.4%FY2026 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.